We’re thrilled to announce that the ESCAPE project has officially reached its recruitment target of 300 patients in its randomized trial! This is a significant milestone in our mission to improve the quality of care for older adults managing chronic heart failure and multimorbidity.

This achievement would not have been possible without the incredible teamwork and dedication of everyone involved. A heartfelt thank you goes to all our clinical trial sites for their tireless efforts in identifying and enrolling patients, to the UMG team for their coordination and leadership, and especially to the care managers who work so closely with patients to ensure they feel supported throughout the process. Your commitment has made this milestone possible.

Now that recruitment is complete, our focus shifts completely to evaluation and implementation of the intervention. The intervention phase is implemented by ESCAPE’s care managers, who play a pivotal role in delivering Blended Collaborative Care (BCC) and working directly with patients to address their individual healthcare needs.

Following this intervention phase, we transition to the post-intervention follow-up period, where we assess the longitudinal effects of the intervention and its impact on patient outcomes at two points. The first assessment is immediately after the end-of-treatment and second is up to 24 months thereafter. While currently over 80% of eligible patients have completed the end-of-treatment assessment, long-term follow-ups will start in March/April 2025.

Hitting our recruitment target marks a significant step forward, but the journey is far from over. With the continued efforts of our dedicated teams and the invaluable participation of our patients, we aim to generate insights that can transform care for this vulnerable population.

Thank you once again to everyone who contributed to this success – together, we’re making a difference!